Varicella Zoster Virus, Glycoprotein E, aa48-135, Recombinant (VZV)

Varicella-zoster virus (VZV) interacts with cell surface heparan sulfate proteoglycans during virus attachment. VZV-gE is a glycoprotein that plays an active or supportive role in VZV cell membrane fusion. VZV-gE was found to enhance the fusogenic potential of VZV gB.\n\nThe protein contains the VZV gE immunodominant regions,amino acids: (48-135).\n\nSpecificity:\nImmunoreactive with sera of VZV-infected individuals\n\nApplications:\nAntigen in ELISA and Western Blot, excellent antigen for detection of VZV with minimal specificity problems.\n\nStorage and Stability:\nMay be stored at 4 degrees C for short-term only. For long-term storage, store at -20 degrees C. Aliquots are stable for at least 6 months at -20 degrees C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

V2100-06

Size

100ug

Form

Supplied as a liquid in 25mM Tris-HCl, 1mM EDTA, 50% glycerol.

Purity

(same/more than) 95% by RP-HPLC, FPLC, or reducing/non-reducing SDS-PAGE Silver Stain. Chromatographically purified.

References

1. Are false negative direct immnufluorescence assays caused by varicella zoster virus gE mutant strains? Taha YA, Quinlivan M, Leedham-Green M, J Med Virol 2004 Aug;73(4):631-5 2. Regulation of varicella-zoster virus-induced cell-to-cell fusion by the endocytosis-competent glycoproteins gH and gE. Pasieka TJ, Maresova L, Grose C, J Virol 2004 Mar;78(6):2884-96 3. The requirement of varicella zoster virus glycoprotein E (gE) for viral replication and effects of glycoprotein I on gE in melanoma cells. Mo C, Lee J, Grose C, Virology 2002 Dec 20;304(2):176-86 4. Phosphorylation by the varicella-zoster virus ORF47 protein serine kinase determines whether endocytosed viral gE traffics to the trans-Golgi network or recycles to the cell membrane. Kenyon TK, Cohen JI, J Virol 2002 Nov;76(21):10980-93 5. Immunogenicity of a recombinant varicella-zoster virus gE-IE63 fusion protein, a putative vaccine candidate against primary infection and zoster reactivation. Jacquet A, Haumont M, Garcia L, Jacobs P, Vaccine 2002 Feb 22;20(11-12):1593-602 6. Varicella-zoster Virus gB and gE coexpression, but not gB or gE alone, leads to abundant fusion and syncytium formation equivalent to those from gH and gL coexpression. Maresova L, Pasieka TJ, J Virol 2001 Oct;75(19):9483-92.